{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:14:55Z","timestamp":1792642495216,"version":"4.5.0"},"reference-count":101,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"NIGMS\/NIH","doi-asserted-by":"publisher","award":["R35GM151109"],"award-info":[{"award-number":["R35GM151109"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIGMS\/NIH","doi-asserted-by":"publisher","award":["K08CA230319"],"award-info":[{"award-number":["K08CA230319"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NCI\/NIH","award":["R35GM151109"],"award-info":[{"award-number":["R35GM151109"]}]},{"name":"NCI\/NIH","award":["K08CA230319"],"award-info":[{"award-number":["K08CA230319"]}]},{"name":"Doris Duke Charitable Foundation","award":["R35GM151109"],"award-info":[{"award-number":["R35GM151109"]}]},{"name":"Doris Duke Charitable Foundation","award":["K08CA230319"],"award-info":[{"award-number":["K08CA230319"]}]},{"name":"Edward P. Evans Foundation","award":["R35GM151109"],"award-info":[{"award-number":["R35GM151109"]}]},{"name":"Edward P. Evans Foundation","award":["K08CA230319"],"award-info":[{"award-number":["K08CA230319"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Next-generation sequencing of samples from patients with acute myeloid leukemia (AML) has revealed several driver gene mutations in adult AML. However, unlike other cancers, AML is defined by relatively few mutations per patient, with a median of 4\u20135 depending on subtype. In this review, we will discuss the most common driver genes found in patients with AML and focus on the most clinically relevant ones that impact treatment strategies. The most common driver gene mutations in AML occur in NPM1 and FLT3, accounting for ~30% each. There are now targeted therapies being tested or already approved for these driver genes. Menin inhibitors, a novel targeted therapy that blocks the function of the menin protein, are in clinical trials for NPM1 driver gene mutant AML after relapse. A number of FLT3 inhibitors are now approved for FLT3 driver gene mutant AML in combination with chemotherapy in the frontline and also as single agent in relapse. Although mutations in IDH1\/2 and TP53 only occur in around 10\u201320% of patients with AML each, they can affect the treatment strategy due to their association with prognosis and availability of targeted agents. While the impact of other driver gene mutations in AML is recognized, there is a lack of data on the actionable impact of those mutations.<\/jats:p>","DOI":"10.3390\/cells13161392","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T03:07:38Z","timestamp":1724296058000},"page":"1392","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Common Driver Mutations in AML: Biological Impact, Clinical Considerations, and Treatment Strategies"],"prefix":"10.3390","volume":"13","author":[{"given":"Tiffany","family":"Nong","sequence":"first","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shefali","family":"Mehra","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4407-6325","authenticated-orcid":false,"given":"Justin","family":"Taylor","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"106727","DOI":"10.1016\/j.leukres.2021.106727","article-title":"A concise review on the molecular genetics of acute myeloid leukemia","volume":"111","author":"Padmakumar","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Saultz, J.N., and Garzon, R. (2016). Acute Myeloid Leukemia: A Concise Review. J. Clin. Med., 5.","DOI":"10.3390\/jcm5030033"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/MOH.0000000000000567","article-title":"Driver mutations in acute myeloid leukemia","volume":"27","author":"Kishtagari","year":"2020","journal-title":"Curr. Opin. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12032-017-0970-x","article-title":"FLT3-ITD and its current role in acute myeloid leukaemia","volume":"34","year":"2017","journal-title":"Med. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e2300229","DOI":"10.1200\/GO.23.00229","article-title":"Burden of AML, 1990\u20132019: Estimates From the Global Burden of Disease Study","volume":"9","author":"Jani","year":"2023","journal-title":"JCO Glob. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1612702","DOI":"10.1155\/2022\/1612702","article-title":"The Global Burden of Leukemia and Its Attributable Factors in 204 Countries and Territories: Findings from the Global Burden of Disease 2019 Study and Projections to 2030","volume":"2022","author":"Du","year":"2022","journal-title":"J. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Mace\u010dkov\u00e1, D., Va\u0148kov\u00e1, L., Holubov\u00e1, M., Jindra, P., Klieber, R., Jandov\u00e1, E., and Pitule, P. (2024). Current knowledge about FLT3 gene mutations, exploring the isoforms, and protein importance in AML. Mol. Biol. Rep., 51.","DOI":"10.1007\/s11033-024-09452-2"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.canep.2015.06.009","article-title":"Prognostic factors of childhood and adolescent acute myeloid leukemia (AML) survival: Evidence from four decades of US population data","volume":"39","author":"Hossain","year":"2015","journal-title":"Cancer Epidemiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40164-020-00170-6","article-title":"Leukemia incidence trends at the global, regional, and national level between 1990 and 2017","volume":"9","author":"Dong","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Song, G.Y., Kim, H.J., Kim, T., Ahn, S.Y., Jung, S.H., Kim, M., Yang, D.H., Lee, J.J., Kim, M.Y., and Cheong, J.W. (2024). Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-57295-5"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1182\/blood.2021012732","article-title":"Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML","volume":"138","author":"Martelli","year":"2021","journal-title":"Blood"},{"key":"ref_17","unstructured":"Levine, R.L., and Mardis, E.R. (2016). Hematology 2016 (ASH Education Program), American Society of Haematology."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Kelemen, K. (2022). The Role of Nucleophosmin 1 (NPM1) Mutation in the Diagnosis and Management of Myeloid Neoplasms. Life, 12.","DOI":"10.3390\/life12010109"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood.V99.1.310","article-title":"FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model","volume":"99","author":"Kelly","year":"2002","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/blood-2004-01-0388","article-title":"In vitro studies of a FLT3 inhibitor combined with chemotherapy: Sequence of administration is important to achieve synergistic cytotoxic effects","volume":"104","author":"Levis","year":"2004","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.leukres.2009.10.001","article-title":"Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse","volume":"34","author":"Ravandi","year":"2010","journal-title":"Leuk. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/leu.2011.97","article-title":"Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia","volume":"25","author":"Schnittger","year":"2011","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"Schlenk","year":"2012","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","article-title":"An update of current treatments for adult acute myeloid leukemia","volume":"127","author":"Dombret","year":"2016","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1182\/blood-2005-01-0178","article-title":"Drug therapy for acute myeloid leukemia","volume":"106","author":"Tallman","year":"2005","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","article-title":"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia","volume":"111","author":"Gale","year":"2008","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nchembio.773","article-title":"Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia","volume":"8","author":"Grembecka","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/2159-8290.CD-22-0366","article-title":"Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia","volume":"13","author":"Uckelmann","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_33","unstructured":"(2024, August 16). A Phase 1\/2, Open-Label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed\/Refractory Leukemias, Including Those Harboring an MLL\/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation. Available online: https:\/\/www.dana-farber.org\/clinical-trials\/19-467."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1182\/blood-2021-146944","article-title":"Safety and Efficacy of Menin Inhibition in Patients (Pts) with MLL-Rearranged and NPM1 Mutant Acute Leukemia: A Phase (Ph) 1, First-in-Human Study of SNDX-5613 (AUGMENT 101)","volume":"138","author":"Stein","year":"2021","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-134942","article-title":"A Phase 1\/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia","volume":"136","author":"Wang","year":"2019","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1182\/blood-2021-152050","article-title":"Preclinical Evaluation of a Novel Orally Bioavailable Menin-MLL Interaction Inhibitor, DSP-5336, for the Treatment of Acute Leukemia Patients with MLL-Rearrangement or NPM1 Mutation","volume":"138","author":"Eguchi","year":"2021","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2022-167674","article-title":"A Phase 1\/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Acute Leukemia Patients with and without Mixed Lineage Leukemia (MLL)-Rearrangement or Nucleophosmin 1 (NPM1) Mutation","volume":"140","author":"Daver","year":"2021","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/blood-2021-153189","article-title":"Phase I\/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndromes and Myelodysplastic\/Myeloproliferative Neoplasms with FLT3 or CBL Mutations","volume":"138","author":"Abuasab","year":"2020","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Hilton, J., Cristea, M., Postel-Vinay, S., Baldini, C., Voskoboynik, M., Edenfield, W., Shapiro, G.I., Cheng, M.L., Vuky, J., and Corr, B. (2022). BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1\/2a Trial. Cancers, 14.","DOI":"10.3390\/cancers14174079"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2006-04-015826","article-title":"FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia","volume":"110","author":"Mead","year":"2007","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Janke, H., Pastore, F., Schumacher, D., Herold, T., Hopfner, K.P., Schneider, S., Berdel, W.E., B\u00fcchner, T., Woermann, B.J., and Subklewe, M. (2014). Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0089560"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e11858","DOI":"10.1016\/j.heliyon.2022.e11858","article-title":"Evaluating the clinical significance of","volume":"8","author":"Moualla","year":"2022","journal-title":"Heliyon"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: Review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/blood-2014-02-554667","article-title":"Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia","volume":"124","author":"Linch","year":"2014","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2013-01-479188","article-title":"Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia","volume":"122","author":"Bullinger","year":"2013","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: A consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_49","first-page":"1","article-title":"Midostaurin the First Targeted Therapy to Improve Survival in AML: Potentially Practice-Changing","volume":"9","author":"Starr","year":"2016","journal-title":"Am. Health Drug Benefits"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Eguchi, M., Minami, Y., Kuzume, A., and Chi, S. (2020). Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Biomedicines, 8.","DOI":"10.3390\/biomedicines8080245"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): A multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1200\/JCO.23.01061","article-title":"Crenolanib and Intensive Chemotherapy in Adults with Newly Diagnosed FLT3-Mutated AML","volume":"42","author":"Wang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood-2013-10-529313","article-title":"Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants","volume":"123","author":"Galanis","year":"2014","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/bloodadvances.2023010619","article-title":"A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia","volume":"8","author":"Levis","year":"2024","journal-title":"Blood Adv."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/ng.2759","article-title":"The landscape of somatic mutations in Down syndrome\u2013related myeloid disorders","volume":"45","author":"Yoshida","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"George, B., Kantarjian, H., Baran, N., Krocker, J.D., and Rios, A. (2021). TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910782"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: Mechanisms, structures, and advances in therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/EDBK_199519","article-title":"Acute Myeloid Leukemia: The Good, the Bad, and the Ugly","volume":"38","author":"Kuykendall","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/blood-2011-11-366062","article-title":"Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies","volume":"119","author":"Medeiros","year":"2012","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.isci.2018.06.002","article-title":"Mutant and Wild-Type Tumor Suppressor p53 Induces p300 Autoacetylation","volume":"4","author":"Kaypee","year":"2018","journal-title":"iScience"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/sj.cdd.4401903","article-title":"p53 in recombination and repair","volume":"13","author":"Gatz","year":"2006","journal-title":"Cell Death Differ."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1128\/MCB.20.20.7450-7459.2000","article-title":"Tumor suppressor p53 is required to modulate BRCA1 expression","volume":"20","author":"Arizti","year":"2000","journal-title":"Mol. Cell Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature25480","article-title":"The landscape of genomic alterations across childhood cancers","volume":"555","author":"Worst","year":"2018","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2022-163044","article-title":"Prognostic Impact of Monoallelic Versus Biallelic TP53 Alterations in Intensively-Treated Adults AML Patients: A Retrospective Study from the ALFA Group","volume":"140","author":"Fenwarth","year":"2022","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41419-018-0463-7","article-title":"APR-246 reactivates mutant p53 by targeting cysteines 124 and 277","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41418-023-01122-3","article-title":"The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells","volume":"30","author":"Wang","year":"2023","journal-title":"Cell Death Differ."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood-2019-131055","article-title":"Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)","volume":"134","author":"Sallman","year":"2019","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1078-0432.CCR-15-0481","article-title":"Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia","volume":"22","author":"Andreeff","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood-2021-147962","article-title":"Phase II Trial of APR-246 in Combination with Azacitidine as Maintenance Therapy for TP53 Mutated AML or MDS Following Allogeneic Stem Cell Transplant","volume":"138","author":"Mishra","year":"2019","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-139752","article-title":"Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy","volume":"136","author":"Zeidan","year":"2020","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","article-title":"The implications of IDH mutations for cancer development and therapy","volume":"18","author":"Pirozzi","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41392-020-00326-0","article-title":"NADPH homeostasis in cancer: Functions, mechanisms and therapeutic implications","volume":"5","author":"Ju","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13073-015-0134-6","article-title":"TET proteins and the control of cytosine demethylation in cancer","volume":"7","author":"Scourzic","year":"2015","journal-title":"Genome Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1073\/pnas.1324297111","article-title":"Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission","volume":"111","author":"Hong","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/s41375-020-01043-x","article-title":"IDH1\/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction-a retrospective propensity score analysis","volume":"35","author":"Kattih","year":"2021","journal-title":"Leukemia"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1182\/blood-2010-02-270926","article-title":"The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3\/ITD status","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood-2010-12-322479","article-title":"The prognostic significance of IDH2 mutations in AML depends on the location of the mutation","volume":"118","author":"Green","year":"2011","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1182\/blood-2013-03-493197","article-title":"Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia","volume":"121","author":"DiNardo","year":"2013","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.24072","article-title":"Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML","volume":"90","author":"DiNardo","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1182\/bloodadvances.2022008282","article-title":"Characteristics and prognostic impact of IDH mutations in AML: A COG, SWOG, and ECOG analysis","volume":"7","author":"Alonzo","year":"2023","journal-title":"Blood Adv."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2022008316","article-title":"Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML","volume":"7","author":"Issa","year":"2023","journal-title":"Blood Adv."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1158\/1078-0432.CCR-20-1820","article-title":"Differentiating the Differentiation Syndrome Associated with IDH Inhibitors in AML","volume":"26","author":"Zeidner","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/jamaoncol.2017.4695","article-title":"Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1\/2 Study","volume":"4","author":"Fathi","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"101523","DOI":"10.1016\/j.tranon.2022.101523","article-title":"The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?","volume":"25","author":"Bhatt","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/bloodadvances.2022009411","article-title":"Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML","volume":"7","author":"Fenaux","year":"2023","journal-title":"Blood Adv."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood.2021014901","article-title":"Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed\/refractory AML: A randomized phase 3 trial","volume":"141","author":"Montesinos","year":"2023","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/2643-3230.BCD-22-0205","article-title":"A Phase Ib\/II Study of Ivosidenib with Venetoclax \u00b1 Azacitidine in IDH1-Mutated Myeloid Malignancies","volume":"4","author":"Lachowiez","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2017-02-734541","article-title":"Diagnosis and classification of hematologic malignancies on the basis of genetics","volume":"130","author":"Taylor","year":"2017","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/16\/1392\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:40:17Z","timestamp":1760110817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/16\/1392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":101,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["cells13161392"],"URL":"https:\/\/doi.org\/10.3390\/cells13161392","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,21]]}}}